Daniel J. O'Connor
CIK 1376847 · President and CEO · last filed 2026-06-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AMAM price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
300 PARK AVENUE, 12TH FLOOR
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DMAC | Director | 0 | $8.74 | $0 | $0 | 2 | 2026-06-03 |
| Ambrx Biopharma, Inc. (AMAM) Delisted | President and CEO | 0 | $28.00 | $0 | -$491.1K | 5 | 2024-03-07 |
| SEELOS THERAPEUTICS, INC. (SEEL) Delisted | Director | 4 | $0.39 | $2 | $9.8K | 7 | 2024-01-08 |
| ZyVersa Therapeutics, Inc. (LSPRW) Delisted | Chief Executive Officer | 42,005 | $0.18 | $7.6K | $0 | 1 | 2022-03-10 |
| ONCOSEC MEDICAL Inc (ONCS) Delisted | CEO and President | 4,368 | $0.28 | $1.2K | -$48.5K | 18 | 2021-05-04 |
| Ayala Pharmaceuticals, Inc. (ADXSW) Delisted | Chief Executive Officer | 618,352 | — | — | -$68.6K | 11 | 2017-07-03 |
| Ayala Pharmaceuticals, Inc. (ADXS.W) Delisted | Chief Executive Officer | 302,710 | — | — | -$247.4K | 39 | 2016-10-04 |
| IMCLONE SYSTEMS INC (IMCL) Delisted | SVP, Interim Gen. Counsel, Sec | — | — | — | $0 | 2 | 2007-02-21 |
Recent Filings · Page 2 of 9
88 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-02 | SEELOS THERAPEUTICS, INC. (SEEL) Delisted | Buy (P) | +16,000 | $9.8K | EDGAR |
| 2022-03-10 | ZyVersa Therapeutics, Inc. (LSPRW) Delisted | Other (J) | +42,005 | $0 | EDGAR |
| 2022-01-06 | SEELOS THERAPEUTICS, INC. (SEEL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-04 | ONCOSEC MEDICAL Inc (ONCS) Delisted | Sell (S) | −3,172 | -$15.4K | EDGAR |
| 2021-02-02 | ONCOSEC MEDICAL Inc (ONCS) Delisted | Sell (S) | −3,413 | -$26.3K | EDGAR |
| 2021-01-08 | SEELOS THERAPEUTICS, INC. (SEEL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-11-03 | ONCOSEC MEDICAL Inc (ONCS) Delisted | Sell (S) | −3,280 | -$12.4K | EDGAR |
| 2020-08-26 | ONCOSEC MEDICAL Inc (ONCS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-08-04 | ONCOSEC MEDICAL Inc (ONCS) Delisted | Sell (S) | −3,133 | -$13.2K | EDGAR |
| 2020-06-03 | ONCOSEC MEDICAL Inc (ONCS) Delisted | Mixed | +46,109 | -$99.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.